Tamoxifen: Friend or Foe for Uterine Health?

Tamoxifen, a vital medication for preventing hormone-sensitive breast cancer recurrence, has been linked to potential alterations in uterine health, including the development or growth of fibroids. While the drug effectively blocks estrogen's effects in breast tissue, it can exhibit estrogen-like properties within the uterus. This may lead to a thickened uterine lining and, in some cases, contribute to fibroid formation or enlargement.

Medical professionals advise that tamoxifen's role in fibroid development is complex, and it's more accurate to say it may be associated with or contribute to fibroids rather than definitively cause them. Establishing a direct causal link for an individual fibroid is challenging due to fibroids' commonality and multiple influencing factors like hormones and age.

Women taking tamoxifen are urged not to discontinue their medication without consulting their doctor, as it significantly reduces breast cancer recurrence risk. Any new or unusual vaginal bleeding, spotting, or discharge, especially after menopause, should be promptly reported to a healthcare provider for evaluation. This is crucial as it could indicate fibroids or other endometrial changes, including a rare risk of endometrial cancer associated with tamoxifen use.